Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over

Nivolumab–relatlimab (Opdualag, Bristol Myers Squibb) is indicated for 'the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older'.

The dosage schedule is available in the summary of product characteristics for nivolumab–relatlimab.

Nivolumab–relatlimab costs £6,135 per 16 mg/ml vial (company submission).

The company has a commercial arrangement. This makes nivolumab–relatlimab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.